tiprankstipranks
Trending News
More News >
Metagenomi, Inc. (MGX)
NASDAQ:MGX
US Market
Advertisement

Metagenomi, Inc. (MGX) AI Stock Analysis

Compare
920 Followers

Top Page

MGX

Metagenomi, Inc.

(NASDAQ:MGX)

Select Model
Select Model
Select Model
Neutral 52 (OpenAI - 4o)
Rating:52Neutral
Price Target:
$2.50
▲(9.17% Upside)
Metagenomi, Inc. exhibits strong revenue growth and positive technical momentum, but faces significant challenges in profitability and cash flow management. The negative P/E ratio and lack of dividend yield highlight ongoing financial struggles. Investors should be cautious of liquidity risks despite the stock's current upward trend.
Positive Factors
Revenue Growth
Strong revenue growth indicates successful market penetration and increased demand for Metagenomi's gene editing technologies, supporting long-term business expansion.
Strategic Partnerships
Strategic partnerships provide a steady revenue stream through milestone payments and royalties, enhancing Metagenomi's market position and innovation capabilities.
Balance Sheet Health
A strong equity position reflects financial stability and provides a solid foundation for future growth and investment in R&D.
Negative Factors
Profitability Challenges
Ongoing profitability challenges suggest high operational costs, which could hinder long-term financial sustainability if not addressed.
Cash Flow Issues
Negative cash flows indicate potential liquidity issues, which may impact the company's ability to fund operations and strategic initiatives over time.
Liquidity Risks
Liquidity risks could constrain Metagenomi's operational flexibility and ability to respond to market opportunities, affecting long-term growth prospects.

Metagenomi, Inc. (MGX) vs. SPDR S&P 500 ETF (SPY)

Metagenomi, Inc. Business Overview & Revenue Model

Company DescriptionMetagenomi, Inc., a gene editing biotechnology company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.
How the Company Makes MoneyMetagenomi, Inc. generates revenue through the development and commercialization of its proprietary gene editing technologies. The company engages in strategic partnerships and collaborations with pharmaceutical and biotechnology companies to co-develop and license its technology for therapeutic applications. These partnerships often involve milestone payments, licensing fees, and royalties based on the successful development and commercialization of gene therapies. Additionally, Metagenomi may receive funding from research grants and government programs aimed at advancing genetic research and innovation.

Metagenomi, Inc. Financial Statement Overview

Summary
Metagenomi, Inc. shows strong revenue growth but struggles with profitability and cash flow management. The balance sheet is improving with positive equity, but liquidity and operational challenges remain significant.
Income Statement
52
Neutral
Metagenomi, Inc. has shown substantial revenue growth over the past years, with a remarkable increase from $243K in 2021 to $52.3M in 2024. However, the company is facing significant profitability challenges, as indicated by negative EBIT and net income margins, suggesting high operational costs or investments outpacing revenue growth. The gross profit margin improved significantly, but the net profit margin remains negative, indicating ongoing losses.
Balance Sheet
45
Neutral
The company's balance sheet shows a strong equity position with positive stockholders' equity in 2024, recovering from negative equity in previous years. The debt-to-equity ratio is relatively low, reflecting manageable leverage levels. However, the consistent negative equity in earlier years and the volatility in asset management could pose risks to financial stability.
Cash Flow
40
Negative
Metagenomi's cash flow statement highlights significant cash outflows, particularly in operating cash flow, which has been negative and worsening. The free cash flow is also negative, indicating potential liquidity challenges. Despite these concerns, the company has maintained substantial cash balances, possibly from financing activities, but sustainability may be an issue if cash burn continues.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue33.77M52.30M44.76M17.20M243.00K
Gross Profit33.77M52.30M40.55M15.47M-144.00K
EBITDA-86.30M-83.49M-74.28M-39.19M-20.75M
Net Income-87.12M-78.06M-68.25M-43.59M-21.44M
Balance Sheet
Total Assets272.28M324.60M364.84M414.49M141.99M
Cash, Cash Equivalents and Short-Term Investments204.99M248.31M271.18M362.13M108.15M
Total Debt42.99M45.78M48.23M18.57M48.93M
Total Liabilities76.45M89.74M500.43M488.91M174.54M
Stockholders Equity195.83M234.86M-135.58M271.68M43.95M
Cash Flow
Free Cash Flow-98.96M-112.19M-101.22M15.75M21.35M
Operating Cash Flow-97.01M-109.07M-91.41M29.72M24.26M
Investing Cash Flow63.41M-88.16M45.73M-122.20M-74.32M
Financing Cash Flow-735.00K84.01M1.01M239.59M39.92M

Metagenomi, Inc. Technical Analysis

Technical Analysis Sentiment
Positive
Last Price2.29
Price Trends
50DMA
2.03
Positive
100DMA
1.85
Positive
200DMA
2.12
Positive
Market Momentum
MACD
0.09
Negative
RSI
61.74
Neutral
STOCH
72.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MGX, the sentiment is Positive. The current price of 2.29 is above the 20-day moving average (MA) of 1.96, above the 50-day MA of 2.03, and above the 200-day MA of 2.12, indicating a bullish trend. The MACD of 0.09 indicates Negative momentum. The RSI at 61.74 is Neutral, neither overbought nor oversold. The STOCH value of 72.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for MGX.

Metagenomi, Inc. Risk Analysis

Metagenomi, Inc. disclosed 76 risk factors in its most recent earnings report. Metagenomi, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Metagenomi, Inc. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (55)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
52
Neutral
$85.95M-37.45%-39.62%6.83%
45
Neutral
$275.59M-4.90-100.00%72.53%
43
Neutral
$104.09M-1.00-9.69%
41
Neutral
$38.96M-0.22239.23%-53.61%-93.14%
55
Neutral
$6.65B3.83-15.92%6.20%10.91%7.18%
* General Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
MGX
Metagenomi, Inc.
2.29
0.12
5.53%
DOMH
Dominari Holdings
6.84
5.13
300.00%
ADAP
Adaptimmune Therapeutics
0.15
-0.80
-84.21%
IMAB
I-MAB
3.48
2.24
180.65%
INZY
Inozyme Pharma
4.00
-1.23
-23.52%
IOBT
IO Biotech
1.58
0.53
50.48%

Metagenomi, Inc. Corporate Events

Business Operations and StrategyExecutive/Board ChangesFinancial Disclosures
Metagenomi Reports Strong Q2 2025 Financial Results
Positive
Aug 12, 2025

Metagenomi, Inc. reported its second quarter 2025 financial results and business updates, highlighting significant advancements in its gene editing technologies. The company presented three abstracts at the American Society of Gene & Cell Therapy, showcasing early proof-of-concept data for its gene editing technologies, and announced a strong cash position of $205 million, expected to support operations into 2027. Metagenomi continues to advance its MGX-001 program for Hemophilia A and its collaboration with Ionis in cardiometabolic indications, while also enhancing its board with the appointment of Laurence Reid, Ph.D. The company is focused on operational efficiency and investment in its pipeline and AI-driven metagenomics platform.

The most recent analyst rating on (MGX) stock is a Buy with a $21.00 price target. To see the full list of analyst forecasts on Metagenomi, Inc. stock, see the MGX Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Sep 26, 2025